Pediatric tonsillopharyngitis - An evaluation of cefprozil in Indian patients

被引：3

作者：

Gupta N. ^{[1
]}

Mukherjee A. ^{[2
]}

Moharana A.K. ^{[3
,4
]}

机构：

[1] Batra Hosp. and Med. Research Center, New Delhi

[2] Batra Hosp. and Med. Research Center, Salt Lake City, Kolkata

[3] Ranbaxy Laboratories Ltd., New Delhi

[4] Delhi-110032, V-7, Naveen Shahdara

来源：

The Indian Journal of Pediatrics | 2004年 / 71卷 / 7期

关键词：

Cefprozil; Penicillin; Pharyngitis; Streptococcal tonsillopharyngitis;

D O I：

10.1007/BF02724119

中图分类号：

学科分类号：

摘要：

Objective: The emergence of penicillin resistant strains and the presence of co-pathogens have made the treatment of bacterial infections in children a challenge. Streptococcal tonsillopharyngitis, which is a common infection has been well treated with cefprozil, a novel third generation cephalosporin. The aim of the present study was to evaluate cefprozil in pediatric tonsillopharyngitis. An assessment of the clinical cure and bacteriological eradication rates and an overall tolerability was made. Methods: It was a prospective, open, non-comparative multicentric study. 316 children (mean age 6.61 years) with tonsillopharyngitis were included. Patients were given cefprozil susp 15 mg/kg/day in two divided doses a day for 10 days. Results: A clinical cure of 96.6% and bacteriological eradication of 94.29% was achieved with cefprozil. Overall tolerability of cefprozil was assessed by physicians and 46% rated tolerability of cefprozil as excellent, 38% as very good, 10% as good, 6% as fair and none as poor. Conclusion: Cefprozil has been found to be an excellent drug of superior microbiological and clinical activity in the treatment of pediatric patients with tonsillopharyngitis. The drug also has an expanded spectrum.

引用

页码：601 / 605

页数：4

共 18 条

[1]

Milatovic D., Adam D., Hamilton H., Materman E., Cefprozil versus penicillin V in the treatment of streptococcal tonsillopharyngitis, Antimicrob Agents Chemother, 37, pp. 1620-1623, (1993)

[2]

Sinkinson C.A., Pichichero M.E., Centor R.M., The compromises of managing acute pharyngitis, Emerg Med, 9, pp. 161-168, (1988)

[3]

Gastanaduy A.S., Kaplan E.L., Huwe B.B., Et al., Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis, Lancet, 11, pp. 498-501, (1980)

[4]

Brook L., The role of β lactamase producing bacteria in the persistence of streptococcal bacterial infection, Rev Infect Dis, 6, pp. 601-607, (1984)

[5]

Wiseman L.R., Benfield P., Cefprozil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential, Drugs, 45, 2, pp. 295-317, (1993)

[6]

De La Garza C.A., Nolen T.M., Rogan M.P., Cefprozil vs. erythromycin in streptococcal tonsillopharyngitis, Infections in Medicine, 9, SUPPL. E, pp. 8-20, (1992)

[7]

Barbarash R.A., Solomon E., Thieneman Jr. A., Stricker W.E., Scott J.C., Et al., Cefprozil versus amoxicillin/clavulanate in mild to moderate lower respiratory tract infections, Infections in Medicine, 9, SUPPL. E, pp. 40-47, (1992)

[8]

Wilber R.B., Hamilton H., Leroy A., Gres J., Durham S.J., Et al., Cefprozil vs. cefaclor in the treatment of lower respiratory tract infections, Infections in Medicine, 9, SUPPL. C, pp. 45-46, (1992)

[9]

Solomon E., McCarty J.M., Morman M.R., Ginsberg D., Nolen T.M., Et al., Comparison of cefprozil and amoxicillin/clavulanate potassium in the treatment of skin and skin structure infections in adults, Advances in Therapy, 9, pp. 156-165, (1992)

[10]

Iravani A., Doyle C.A., Durham S.J., Wilber R.B., Cefprozil vs. cefaclor in the treatment of acute and uncomplicated urinary tract infections, Clinical Therapeutics, 14, pp. 314-326, (1992)

← 1 2 →